Here at the Scleroderma Research Foundation, research is at the center of all we do to find a cure—and that's only possible because of the dedicated support of our community....
Read More
Dr. Gordon will have oversight over the SRF’s global clinical trial program CONQUEST and will contribute to the research program across the SRF portfolio San Francisco, CA (January 25, 2024)…
CONQUEST Featured in "Endpoints News" SRF Chairman of the Board Luke Evnin, PhD, recently sat down with Andrew Dunn of "Endpoints News" to announce that CONQUEST has received FDA OK...
Read More
SAN FRANCISCO, October 3, 2023 — The Scleroderma Research Foundation (SRF), the nation’s largest non-profit funder of scleroderma research, today announced that Boehringer Ingelheim, a leading research-driven biopharmaceutical company, will…
• Sanofi is inaugural partner • Initial focus on Interstitial Lung Disease Secondary to Scleroderma • SRF will submit and hold the IND as the trial Sponsor SAN FRANCISCO, August...
Read More
Today, the Scleroderma Research Foundation announces the launch of CONQUEST, a highly innovative platform clinical trial designed to rapidly advance promising treatments for scleroderma. Industry partner, Sanofi, will contribute the first experimental...
Read More
